Device IPO Class of 2007 Making News, Some Returns
This article was originally published in Start Up
The merger of Accuray and TomoTherapy would combine two of the 11 medical device companies that went public in 2007, a class of companies that has produced mixed results.
You may also be interested in...
Radiation oncology is a very attractive market indeed. It's a $3 billion-plus capital equipment market predicted to experience a compound annual growth rate of 10 to 15% in the next several years, with the image-guided segment expected to grow at a 35% rate. Approximately 30% of the market is up for grabs over the next three years, as institutions replace old and obsolete equipment. Can small company TomoTherapy sustain the lead it has gained with a new image-guided system that increases the precision of cancer targeting and spares normal tissues, once entrenched multi-billion dollar radiation oncology companies begin to offer aggressive competition?
Building a new product market is never easy, and the chances for a start-up in capital equipment are especially slim. Accuray has the scars to prove it. But after a long haul, it appears to be succeeding in building a market in radiosurgery.
EnteroMedics recently earned the distinction of closing the second-largest financing for a private medical device company in 2006. Its success was undoubtedly due to the company's attractive position at the junction of two of the device industry's hottest markets: obesity and neuromodulation. EnteroMedics is developing an implantable impulse generator that it hopes will address multiple mechanisms in obesity.